159 related articles for article (PubMed ID: 12079618)
1. Does hypertriglyceridemia present an indication for pioglitazone therapy in diabetes?
Kane JP
Diabetes Technol Ther; 2002; 4(2):153-5. PubMed ID: 12079618
[No Abstract] [Full Text] [Related]
2. Pioglitazone and rosiglitazone for diabetes.
Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
[TBL] [Abstract][Full Text] [Related]
3. [Against insulin resistance. Insulin sensitizers].
Verspohl EJ; Weiland F
Pharm Unserer Zeit; 2002; 31(3):280-92. PubMed ID: 12071125
[No Abstract] [Full Text] [Related]
4. Tissue triglyceride levels in type 2 diabetes and the role of thiazolidinediones in reversing the effects of tissue hypertriglyceridemia: review of the evidence in animals and humans.
Bell DS; Ovalle F
Endocr Pract; 2001; 7(2):135-8. PubMed ID: 11421558
[No Abstract] [Full Text] [Related]
5. [Clinical efficacy of Pioglitazone (AD-4833)].
Kaneko T; Baba S
Nihon Rinsho; 1997 Nov; 55 Suppl():142-6. PubMed ID: 9434458
[No Abstract] [Full Text] [Related]
6. [Pioglitazone].
Kobayashi M; Iwata M; Hiratani K
Nihon Rinsho; 2002 Sep; 60 Suppl 9():429-37. PubMed ID: 12387029
[No Abstract] [Full Text] [Related]
7. Pioglitazone.
Lawrence JM; Reckless JP
Int J Clin Pract; 2000 Nov; 54(9):614-8. PubMed ID: 11220991
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review.
Chilcott J; Wight J; Lloyd Jones M; Tappenden P
Health Technol Assess; 2001; 5(19):1-61. PubMed ID: 11701097
[No Abstract] [Full Text] [Related]
9. [Thiazolidinediones].
Scheen AJ; Paquot N; Letiexhe MR; Lefèbvre PJ
Journ Annu Diabetol Hotel Dieu; 1999; ():213-29. PubMed ID: 10732419
[No Abstract] [Full Text] [Related]
10. [First insulin sensitizer approved in Germany. Insulin resistance in type 2 diabetes can be treated].
MMW Fortschr Med; 2000 Sep; 142(36):50. PubMed ID: 11021073
[No Abstract] [Full Text] [Related]
11. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers.
Hofmann CA; Colca JR
Diabetes Care; 1992 Aug; 15(8):1075-8. PubMed ID: 1505314
[No Abstract] [Full Text] [Related]
12. [Causal therapy of type 2 diabetes. Determining the cause of insulin resistance early].
MMW Fortschr Med; 2000 Nov; 142(47):56. PubMed ID: 11143782
[No Abstract] [Full Text] [Related]
13. Actos (pioglitazone): a new treatment for type 2 diabetes.
Lawrence JM; Reckless JP
Hosp Med; 2001 Jul; 62(7):411-6. PubMed ID: 11480129
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
Kitaoka H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():464-9. PubMed ID: 12387035
[No Abstract] [Full Text] [Related]
16. [Troglitazone, an insulin action enhancer--a drug of precision to treat adult-onset diabetes].
Westerbacka J; Yki-Järvinen H
Duodecim; 1997; 113(19):1847-8. PubMed ID: 10892078
[No Abstract] [Full Text] [Related]
17. Marked improvement of glycaemic control with pioglitazone in a Type 2 diabetic patient associated with Charcot-Marie-Tooth disease.
Ota T; Osawa K
Diabet Med; 2003 May; 20(5):420-1. PubMed ID: 12752495
[No Abstract] [Full Text] [Related]
18. [Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
Lotz N
MMW Fortschr Med; 2002 Jan; 144(3-4):48-50. PubMed ID: 11862793
[No Abstract] [Full Text] [Related]
19. Rosiglitazone monotherapy and type 2 diabetes.
Lawrence IG
Diabet Med; 2001 Nov; 18 Suppl 4():6-8. PubMed ID: 11989215
[No Abstract] [Full Text] [Related]
20. [Type II diabetes mellitus. Rosiglitazone is effective against insulin resistance].
Oberpichler-Schwenk H
Med Monatsschr Pharm; 1999 Sep; 22(9):288-9. PubMed ID: 10577070
[No Abstract] [Full Text] [Related]
[Next] [New Search]
